|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Factor Xa (FXa) inhibitors, used for stroke prevention in atrial fibrillation and venous thromboembolism treatment and prevention, are the dominant non-Vitamin K oral anticoagulants on the market.
|
28843518 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Factor Xa-inhibitor apixaban is an oral anticoagulant prescribed in atrial fibrillation (AF) for stroke prevention.
|
31564018 |
2020 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
A significant decrease in coagulation time, and increases in FXa and thrombin were exhibited in the PS+ blood cells and MPs from patients with AF treated with PVI, whereas these alterations were inhibited by either lactadherin or anti‑tissue factor (P<0.01).
|
29039531 |
2017 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the NOACs, apixaban - a very specific antagonist of activated factor Xa - has pharmacokinetic and pharmacodynamic properties that allow significant efficacy in AF management.
|
29034832 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation.
|
28283738 |
2017 |
|
Atrial Fibrillation
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
|
29538002 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apixaban (APX) is a direct inhibitor of factor X (FXa) approved for prophylaxis and treatment of deep venous thrombosis and atrial fibrillation.
|
28769809 |
2017 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background and Purpose- Edoxaban is a direct oral factor Xa inhibitor with proven efficacy and safety among patients with atrial fibrillation.
|
30355093 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Betrixaban is an oral, specific and direct inhibitor of human coagulation factor Xa with demonstrated efficacy and safety for the prevention of VTE in patients undergoing total knee replacement and in patients with nonvalvular atrial fibrillation.
|
29119147 |
2017 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Coagulation factor Xa activates the protease-activated receptor 2 (PAR2) and causes tissue fibrosis; however, the effects of Xa inhibitor edoxaban on atrial fibrosis and atrial fibrillation (AF) have not been investigated.
|
30874892 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with warfarin, apixaban, a factor Xa inhibitor, has been shown to reduce the risk of stroke and major bleeding in nonvalvular AF.
|
28595862 |
2017 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dabigatran - a direct thrombin inhibitor, apixaban and rivaroxaban - direct factor Xa inhibitors are now largely used for anticoagulation in patients with nonvalvular atrial fibrillation and in patients with venous thromboembolism.
|
28412907 |
2017 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF).
|
30976787 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Edoxaban is a new oral direct factor Xa inhibitor that has been recently approved for treating VTE in patients who have already been treated with a parenteral anticoagulant and for the prevention of stroke and non-central nervous system systemic embolism in patients with nonvalvular atrial fibrillation.
|
27811198 |
2017 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Edoxaban is an orally active, direct factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation and for the treatment of venous thromboembolism.
|
28512699 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Edoxaban, a direct factor Xa inhibitor, is noninferior vs warfarin for the prevention of stroke or systemic embolism with less major bleeding in patients with nonvalvular AF.
|
29663464 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction Study 48) was a randomized, double-blind trial comparing edoxaban with warfarin in patients with AF followed for 2.8 years.
|
31296289 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) was a multinational randomized trial of the oral factor Xa inhibitor edoxaban in patients with atrial fibrillation and a CHADS<sub>2</sub> score ≥2.
|
30586727 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Event rates will be compared with event rates reported in the PREvention oF thromboembolic events-European Registry in Atrial Fibrillation in atrial fibrillation (PREFER in AF) and PREFER in AF Prolongation registries, and in the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48 study datasets.
|
30540648 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we analyze bleeding outcomes according to the ISTH (International Society on Thrombosis and Hemostasis), TIMI (Thrombolysis in Myocardial Infarction), GUSTO (Global Usage of Strategies to Open Occluded Arteries), and BARC (Bleeding Academic Research Consortium) bleeding scales in the ENGAGE AF (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation)-TIMI 48 trial (NCT00781391) of edoxaban versus warfarin.
|
31597460 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, further studies are needed to further define the efficacy and safety of performing AF ablation with uninterrupted factor XA inhibitors or direct thrombin inhibitors.Methods and Results:We have performed CA of AF without discontinuation of either VKA or DOAC therapy since April 2014.
|
29657252 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a prospective echocardiographic substudy of the Effective Anticoagulation with Factor Xa Next Generation in AF-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) study, 971 patients underwent transthoracic echocardiography.
|
31777160 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, Factor Xa inhibitors reduce PV spontaneous activities and may modulate occurrence of atrial fibrillation by inhibiting PAR1 and reducing the I<sub>Na-late</sub> in PVs.
|
30017860 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
In ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), the factor Xa inhibitor edoxaban was noninferior to warfarin in preventing stroke or systemic embolic events and significantly reduced bleeding and cardiovascular mortality.
|
28077507 |
2017 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the "dabigatran bridge" group, the activated partial thromboplastin time was significantly longer, and coagulation markers (soluble fibrin monomer and thrombin-antithrombin complexes) were significantly lower than in the interrupted group before ablation.The "dabigatran bridge" seems to be a reasonable anticoagulation protocol to minimize the thromboembolic risk while ensuring safety in patients undergoing AF ablation and taking factor Xa inhibitors.
|
31735780 |
2019 |